Van Lanschot Kempen Investment Management N.V. Has $5.37 Million Stock Holdings in Bristol Myers Squibb Company $BMY

Key Points

• Van Lanschot Kempen Investment Management N.V. increased its stake in Bristol Myers Squibb by 12.2%, owning 88,093 shares valued at approximately $5.37 million following a recent acquisition.
• Bristol Myers Squibb reported EPS of $1.46 for the last quarter, surpassing expectations, and generated revenues of $12.27 billion, indicating a growth of 0.6% year-over-year.
• The company recently announced a quarterly dividend of $0.62 per share, representing a dividend yield of 5.1% and a payout ratio of 100%.

Van Lanschot Kempen Investment Management N.V. lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 12.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 88,093 shares of the biopharmaceutical company's stock after acquiring an additional 9,581 shares during the period. Van Lanschot Kempen Investment Management N.V.'s holdings in Bristol Myers Squibb were worth $5,373,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in BMY. Pinney & Scofield Inc. bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $25,000. Park Square Financial Group LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at $26,000. Transce3nd LLC bought a new position in Bristol Myers Squibb in the fourth quarter valued at $28,000. Global Wealth Strategies & Associates boosted its stake in shares of Bristol Myers Squibb by 137.5% during the 1st quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 275 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Bristol Myers Squibb during the 1st quarter worth about $31,000. Institutional investors own 76.41% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on BMY shares. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Daiwa America downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Citigroup reduced their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research note on Friday, August 1st. Morgan Stanley restated a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $56.38.

Bristol Myers Squibb Stock Performance

Shares of BMY traded down $0.8660 during midday trading on Monday, reaching $47.0540. The stock had a trading volume of 2,969,372 shares, compared to its average volume of 13,198,388. The firm has a 50 day simple moving average of $47.06 and a 200-day simple moving average of $51.01. Bristol Myers Squibb Company has a one year low of $42.96 and a one year high of $63.33. The firm has a market cap of $95.78 billion, a PE ratio of 18.98, a P/E/G ratio of 2.45 and a beta of 0.36. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company's quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the firm posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were paid a $0.62 dividend. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.3%. Bristol Myers Squibb's dividend payout ratio is 100.00%.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.